Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
226 participants
INTERVENTIONAL
2014-05-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The extract of G. biloba (EGb) is composed of different terpene trilactones, i.e., ginkgolides A, B, C, J and bilobalide, many flavonol glycosides, biflavones and alkylphenols . The major flavonoids in the extract are kaempferol, quercetin and isorhamnetin\] whose metabolites were found in the blood of rats and in human urine after oral administration of EGb. Due to its actions as an anti-inflammatory and antioxidant, EGb has been largely used in the treatment of Alzheimer's disease, pre-menstrual syndrome, cerebrovascular insufficiency and peripheral arterial occlusive disease . In folk medicine, EGb is used as a vermifuge, to induce labor, for the treatment of bronchitis, chronic rhinitis, chilblains, arthritis and edema . The aim of this study was to evaluate the effect of oral supplementation of Ginkgo Biloba extract on the fetal weight as well as feto-maternal blood flow in cases of intrauterine growth restriction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01352234
The Effect of Omega 3 on Pregnancy Complicated by Asymmetrical Intrauterine Growth Restriction
NCT02696577
Aspirin in Asymmetrically Intrauterine Growth
NCT03038607
Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial
NCT02145767
Choline Supplementation on Fetal Growth in Gestational Diabetes Mellitus
NCT04302168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ginkgo Biloba Extract group
This group received Ginko Biloba, two tablets per day
Ginkgo Biloba Extract
Placebo group
This group received placebo two tablets per day .
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ginkgo Biloba Extract
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pregnant women whose pregnancy was complicated with intra uterine growth restriction (IUGR).
* Normal Doppler indices in uterine, umbilical and middle cerebral arteries at time of recruitment.
Exclusion Criteria
* Hypertension,
* Fetal congenital anomalies,
* Previous history of congenital anomalies or chromosomal abnormalities.
* Diabetes Mellitus
* Premature pre-labor rupture of membranes
* Antepartum hemorrhage
20 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
mohamad sayed abdellah
Dr
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Tibonina/ IUGR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.